Search
Search Results
-
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing
BackgroundAlthough various companion diagnostic tests of ALK fusion gene-rearrangement are approved, few reports have assessed the concordance of ALK ...
-
Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement
BackgroundAlthough some studies have assessed the correlation between computed tomography (CT) features and anaplastic lymphoma kinase (ALK)...
-
ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression
ALK-positive ( +) large B cell lymphoma (ALK + LBCL) is a rare distinct subtype of diffuse large B cell lymphoma presenting with high stage and...
-
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
BackgroundTimely identification of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement status in...
-
ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report
BackgroundAnaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC) is an extremely rare tumor and ALK-RCC that mimics...
-
Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma
BackgroundAnaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) improve outcomes for non-small-cell lung cancer (NSCLC) patients with ALK ...
-
Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
BackgroundRearrangements in the anaplastic lymphoma kinase ( ALK ) gene define a molecular subgroup of non-small-cell lung carcinoma (NSCLC) that...
-
Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
Anaplastic large cell lymphomas (ALCL) are mature T-cell neoplasms, approximately half of which harbor rearrangements of the ALK gene that confer a...
-
Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement
Systemic anaplastic lymphoma kinase-negative (ALK-) anaplastic large cell lymphoma (ALCL) comprises a genomically heterogeneous disease that is...
-
Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and ALK: Report of Three New Cases in the Head and Neck Region and Literature Review
BackgroundRhabdomyosarcoma (RMS) harboring EWSR1/FUS-TFCP2 fusions has been recently described as a distinct form of RMS with an aggressive course...
-
ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature
ALK-rearranged renal cell carcinoma (ALK-RCC) is a very rare novel molecularly defined entity in the recently published fifth edition of the World...
-
Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
Anaplastic lymphoma kinase ( ALK ) gene fusion is a classic driver mutation in non-small cell lung cancer (NSCLC); however, ALK double-fusion variants...
-
Comparison of two immunohistochemical staining protocols for ALK demonstrates non-inferiority of a 5A4 clone-based protocol versus an ALK01 clone-based protocol for the diagnosis of ALK + anaplastic large cell lymphoma
Detection of ALK rearrangement and/or expression of the ALK protein is an essential component in the evaluation of many neoplasms. Variability has...
-
EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis
BackgroundAccumulating evidence links the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement to...
-
Novel NONO::TFE3 fusion and ALK co-expression identified in a subset of cutaneous microcystic/reticular schwannoma
Microcystic/reticular schwannoma (MRS) is a benign variant of schwannoma with a predilection for the gastrointestinal tract and skin. To date,...
-
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
BackgroundRandomized trials have demonstrated that anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) can be safe and efficacious...
-
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
BackgroundAnaplastic lymphoma kinase (ALK)–tyrosine kinase inhibitors (TKIs) have been approved for the therapy of locally advanced non-small cell...
-
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement
PurposeAnaplastic lymphoma kinase (ALK) gene rearrangement exists in approximately 3–7% of non-small cell lung cancer (NSCLC) and more than 15% split...
-
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Anaplastic lymphoma kinase ( ALK ) alterations (activating mutations, amplifications, and fusions/rearrangements) occur in ~3.3% of cancers. ALK ...
-
New perspectives for targeting therapy in ALK-positive human cancers
Anaplastic lymphoma kinase (ALK) is a member of the insulin receptor protein-tyrosine kinase superfamily and was first discovered in anaplastic...
